Short answer
IDEAYA Biosciences, Inc. (IDYA) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results announced for quarter ended March 31, 2026.
IDEAYA Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results announced for quarter ended March 31, 2026
- Full results and management commentary furnished in Exhibit 99.1
- Investor focus: cash position, R&D spending, pipeline progress, and any guidance in the attached release
Item EX-99.1 · Exhibit EX-99.1
- OptimUM-02 met its primary endpoint, cutting progression risk 58%; median PFS improved to 6.9 months versus 3.1 months
- ORR reached 37.1% versus 5.8%, including 5 complete responses; overall survival remains immature
- FDA accepted RTOR participation; IDEAYA targets first pre-submission in May and NDA filing in H2 2026
- Cash, equivalents and marketable securities totaled $972.9 million; runway guidance into 2030 unchanged
- Q1 net loss was $98.5 million, with R&D expenses of $95.7 million and $76.8 million quarterly cash-balance decline
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IDEAYA Biosciences, Inc. 8-K filings
Get the next IDYA 8-K as it lands
Follow IDYA for push alerts, or ask the research agent what this filing means.